Omnitrope approval raises concerns in biotech industry

The FDA's recent approval of a generic version of Pfizer's biotech drug Genotropin has raised concerns in the industry about a possible change in approval of copies of biotech drugs. The biotech industry has long argued its products are too complex to be copied safely, and Congress and the FDA hesitated allowing copies; but the generics industry is pushing for a more flexible policy.

View Full Article in:

San Jose Mercury News (Calif.) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC